Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc.

Plain English (For Everyone)

A company called Sigray sued another company, Zeiss, for using their patented X-ray microscopy method for inspecting computer chips. However, the court found that Sigray's patent wasn't new because a similar method was already described in an older document (prior art). Therefore, Sigray's patent was invalidated, and they lost the case.

For Legal Practitioners

The Federal Circuit affirmed summary judgment of non-infringement and invalidity, holding that the asserted claims of the '087 patent were anticipated by the '315 patent. The court found that the '315 patent disclosed all elements of the asserted claims, including the specific arrangement of a focusing optic and detector for X-ray microscopy of semiconductor wafers, thereby invalidating the patent under 35 U.S.C. § 102(a).

For Law Students

This case illustrates the doctrine of anticipation under 35 U.S.C. § 102(a). The Federal Circuit affirmed that a prior art reference ('315 patent) anticipated Sigray's patent ('087 patent) because it disclosed every element of Sigray's claimed method for X-ray microscopy inspection of semiconductor wafers, leading to summary judgment of invalidity.

Newsroom Summary

A patent dispute over X-ray microscopy technology for semiconductor inspection has been resolved, with the Federal Circuit affirming that the patent in question was invalid due to prior art. The court found that a previously existing document described the same invention, negating its novelty.

Standard of Review

De novo review. The Federal Circuit reviews a district court's grant of summary judgment of non-infringement and patent invalidity without deference, meaning it examines the evidence and legal conclusions anew.

Procedural Posture

The case reached the Federal Circuit on appeal from the United States District Court for the Northern District of California, which granted summary judgment of non-infringement and patent invalidity in favor of Carl Zeiss X-Ray Microscopy, Inc. (Zeiss).

Burden of Proof

The burden of proof for patent invalidity based on anticipation rests with the party asserting invalidity (Zeiss). The standard of proof is clear and convincing evidence. However, on summary judgment, the court determines if there is a genuine dispute of material fact.

Legal Tests Applied

Statutory References

Key Legal Definitions

Rule Statements

A prior art reference anticipates a claim if it discloses each and every element of the claim.

The '315 patent discloses all the elements of the asserted claims of the '087 patent.

Scenario: You are a small inventor who has developed a new type of drone technology. You discover a scientific paper published five years ago that describes a very similar drone design and its operational method.

Your Rights: Your right to obtain a patent for your drone technology may be compromised if the prior art paper fully discloses all elements of your invention.

What To Do: Consult with a patent attorney immediately to assess the prior art's impact on your patentability and to understand if your invention can be distinguished or if claims need to be narrowed.

Scenario: Your company is developing a new manufacturing process. Before filing a patent, you want to ensure your invention is novel and non-obvious.

Your Rights: You have the right to seek patent protection for novel and non-obvious inventions, but this right is limited by existing prior art.

What To Do: Conduct a thorough prior art search and work with a patent attorney to analyze the search results and draft claims that clearly differentiate your invention from existing technologies.

Is it legal to patent an invention that is very similar to something described in an old scientific journal?

No, it is generally not legal to patent an invention if a single piece of prior art (like a scientific journal article) fully describes every element of your invention. This is because the invention would not be considered novel under patent law.

This applies to patent law in the United States, governed by statutes like 35 U.S.C. § 102.

For Patent Holders

Patent holders must be vigilant about the scope and novelty of their claims, as existing prior art can easily invalidate a patent, especially if the claims are broad or do not clearly distinguish from prior disclosures.

For Patent Applicants

Applicants must conduct thorough prior art searches before filing and carefully draft claims to ensure their invention is truly novel and non-obvious, avoiding broad claims that might be anticipated by existing technology.

For Competitors in Technology Fields

Competitors can use prior art to challenge the validity of existing patents, potentially clearing the way for their own products or processes if a patent is found to be invalid.

Q: What is Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc. about?

Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc. is a case decided by Federal Circuit on May 23, 2025.

Q: What court decided Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc.?

Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc. was decided by the Federal Circuit, which is part of the federal judiciary. This is a federal appellate court.

Q: When was Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc. decided?

Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc. was decided on May 23, 2025.

Q: What is the citation for Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc.?

The citation for Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc. is 137 F.4th 1372. Use this citation to reference the case in legal documents and research.

Q: What was the main issue in Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc.?

The main issue was whether Sigray's patent for a method of inspecting semiconductor wafers using X-ray microscopy was valid, or if it was anticipated by prior art.

Q: What specific technology was involved in this patent dispute?

The dispute involved a method for inspecting semiconductor wafers using X-ray microscopy.

Q: What was the outcome of the case for Sigray, Inc.?

Sigray, Inc. lost its case because its patent was found to be invalid due to anticipation by prior art, and the district court's grant of summary judgment in favor of Zeiss was affirmed.

Q: What is the significance of the '087 patent and the '315 patent in this case?

The '087 patent is Sigray's asserted patent, while the '315 patent is the prior art reference that the court found anticipated the '087 patent's claims.

Q: Is Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc. published?

Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc. is a published, precedential opinion. Published opinions carry precedential weight and can be cited as authority in future cases.

Q: What topics does Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc. cover?

Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc. covers the following legal topics: Patent obviousness under 35 U.S.C. § 103, Claim construction in patent law, Scanning electron microscope calibration, Prior art analysis in patent validity, Motivation to combine prior art references, Secondary considerations of non-obviousness.

Q: What was the ruling in Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc.?

The court ruled in favor of the defendant in Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc.. Key holdings: The Federal Circuit affirmed the district court's grant of summary judgment of non-infringement, finding that the asserted claims of Sigray's patent were anticipated by the prior art.; The court determined that the prior art reference, 'The Handbook of X-Ray Spectrometry,' disclosed all the limitations of Sigray's asserted claims, specifically the use of a "focusing optic" to direct X-rays onto the semiconductor wafer.; The court rejected Sigray's argument that the 'focusing optic' in the prior art was not the same as the 'focusing optic' recited in the claims, finding that the prior art clearly taught the use of such a optic for directing X-rays.; The court found that Sigray's patent was invalid for anticipation under 35 U.S.C. § 102(a)(1) because the prior art reference disclosed every element of the challenged claims.; The Federal Circuit concluded that no reasonable jury could find infringement given the clear disclosure of the asserted claims in the prior art..

Q: Why is Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc. important?

Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc. has an impact score of 15/100, indicating narrow legal impact. This decision reinforces the importance of thorough prior art searches in patent prosecution and litigation. It highlights how specific disclosures in existing literature can render new patent claims invalid for anticipation, even if the patent holder believes their invention is novel. Companies involved in technology sectors with established prior art should pay close attention to how courts interpret claim elements against such references.

Q: What precedent does Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc. set?

Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc. established the following key holdings: (1) The Federal Circuit affirmed the district court's grant of summary judgment of non-infringement, finding that the asserted claims of Sigray's patent were anticipated by the prior art. (2) The court determined that the prior art reference, 'The Handbook of X-Ray Spectrometry,' disclosed all the limitations of Sigray's asserted claims, specifically the use of a "focusing optic" to direct X-rays onto the semiconductor wafer. (3) The court rejected Sigray's argument that the 'focusing optic' in the prior art was not the same as the 'focusing optic' recited in the claims, finding that the prior art clearly taught the use of such a optic for directing X-rays. (4) The court found that Sigray's patent was invalid for anticipation under 35 U.S.C. § 102(a)(1) because the prior art reference disclosed every element of the challenged claims. (5) The Federal Circuit concluded that no reasonable jury could find infringement given the clear disclosure of the asserted claims in the prior art.

Q: What are the key holdings in Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc.?

1. The Federal Circuit affirmed the district court's grant of summary judgment of non-infringement, finding that the asserted claims of Sigray's patent were anticipated by the prior art. 2. The court determined that the prior art reference, 'The Handbook of X-Ray Spectrometry,' disclosed all the limitations of Sigray's asserted claims, specifically the use of a "focusing optic" to direct X-rays onto the semiconductor wafer. 3. The court rejected Sigray's argument that the 'focusing optic' in the prior art was not the same as the 'focusing optic' recited in the claims, finding that the prior art clearly taught the use of such a optic for directing X-rays. 4. The court found that Sigray's patent was invalid for anticipation under 35 U.S.C. § 102(a)(1) because the prior art reference disclosed every element of the challenged claims. 5. The Federal Circuit concluded that no reasonable jury could find infringement given the clear disclosure of the asserted claims in the prior art.

Q: What cases are related to Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc.?

Precedent cases cited or related to Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc.: None cited in the provided excerpt..

Q: What is 'anticipation' in patent law?

Anticipation means that a prior art reference disclosed every single element of a patent claim before the patent applicant invented it. If a claim is anticipated, it is invalid.

Q: What was the prior art in this case?

The prior art was a patent referred to as the '315 patent, which described a method for X-ray microscopy inspection.

Q: Did the court find Sigray's patent to be novel?

No, the court found that Sigray's patent was not novel because the '315 patent disclosed all the elements of Sigray's claimed invention.

Q: What is the consequence of a patent claim being anticipated?

If a patent claim is found to be anticipated by prior art, that claim is invalid and cannot be enforced.

Q: Can a single prior art reference invalidate an entire patent?

Yes, if that single prior art reference discloses every element of at least one of the patent's claims, that claim is anticipated and invalid. If all claims are invalidated, the entire patent can be deemed invalid.

Q: What is the role of a 'focusing optic' in the context of this patent?

The 'focusing optic' was a key element in Sigray's claimed method for X-ray microscopy inspection. The court found that the prior art ('315 patent) also disclosed the use of such an optic in the claimed arrangement.

Q: How does Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc. affect me?

This decision reinforces the importance of thorough prior art searches in patent prosecution and litigation. It highlights how specific disclosures in existing literature can render new patent claims invalid for anticipation, even if the patent holder believes their invention is novel. Companies involved in technology sectors with established prior art should pay close attention to how courts interpret claim elements against such references. As a decision from a federal appellate court, its reach is national. This case is moderate in legal complexity to understand.

Q: What is the practical implication for inventors after this ruling?

Inventors must be extremely thorough in their prior art searches and ensure their patent claims are narrowly tailored to avoid being anticipated by existing disclosures.

Q: How can a company protect its invention if similar technology already exists?

A company can try to patent improvements or specific applications of existing technology, or draft claims that highlight novel aspects not present in the prior art.

Q: What should I do if I believe my invention is similar to a prior art reference?

Consult with a patent attorney to analyze the prior art and your invention, and to determine the best strategy for patent prosecution or defense.

Q: Does this ruling affect all X-ray microscopy patents?

This ruling specifically addresses the claims of Sigray's '087 patent and its anticipation by the '315 patent. It doesn't automatically invalidate all X-ray microscopy patents, but it highlights the importance of prior art.

Q: What is the historical context of patent law regarding novelty?

The requirement for novelty has been a cornerstone of patent law since its inception, ensuring that patents are granted only for truly new inventions that advance technology.

Q: How has the interpretation of 'prior art' evolved?

Interpretations have evolved to include a wider range of disclosures, from early printed publications to digital content, reflecting technological advancements and the global nature of information.

Q: What was the docket number in Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc.?

The docket number for Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc. is 23-2211. This identifier is used to track the case through the court system.

Q: Can Sigray, Inc. v. Carl Zeiss X-Ray Microscopy, Inc. be appealed?

Potentially — decisions from federal appellate courts can be appealed to the Supreme Court of the United States via a petition for certiorari, though the Court accepts very few cases.

Q: What is the standard of review for summary judgment of patent invalidity?

The Federal Circuit reviews grants of summary judgment of patent invalidity de novo, meaning they examine the record and legal conclusions without deference.

Q: Who had the burden of proof for patent invalidity?

The party asserting invalidity, Carl Zeiss X-Ray Microscopy, Inc., had the burden of proving invalidity by clear and convincing evidence.

Q: What does 'de novo' review mean for this case?

It means the Federal Circuit looked at the case from the beginning, re-evaluating the evidence and legal arguments without giving special weight to the district court's initial decision.

Q: What is the role of the district court in patent invalidity cases?

The district court initially hears patent cases, including motions for summary judgment of invalidity. Its decisions are then subject to review by appellate courts like the Federal Circuit.